Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Valles, Iñaki ^a   Pajares, Maria J ^a,b   Segura, Victor ^a   Guruceaga, Elisabet ^a   Gomez Roman, Javier ^c   Blanco, David ^a,b   Tamura, Akiko ^d   Montuenga, Luis M ^a,b   Pio, Ruben ^a,e  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADAR2 PROTEIN; ARTICLE; ASCL3L1 GENE; CANCER CELL CULTURE; CANCER PROGNOSIS; CHROMOSOME 21Q; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC REGULATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MARS GENE; MRPL3 GENE; PATHOGENESIS; PCBPC1 GENE; RAE GENE; RNA EDITING; RNA METABOLISM; RNA STABILITY; RNA TRANSLATION; RNA TRANSPORT; SNRPB GENE; SNRPE GENE; SPLICEOSOME; TISSUE MICROARRAY; UPREGULATION;

ADENOSINE DEAMINASE; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PROGNOSIS; RNA; RNA-BINDING PROTEINS;

EID: 84864430721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042086     Document Type: Article

References (77)

1. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, et al. ((2011)) Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:: 714--736.
2. Ferlay J, Parkin DM, Steliarova-Foucher E, ((2010)) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:: 765--781.
3. David CJ, Manley JL, ((2010)) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24:: 2343--2364.
4. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, et al. ((2007)) Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 8:: 349--357.
5. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, et al. ((2008)) Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 36:: 6535--6547.
6. Pio R, Montuenga LM, ((2009)) Alternative splicing in lung cancer. J Thorac Oncol 4:: 674--678.
7. Langer W, Sohler F, Leder G, Beckmann G, Seidel H, et al. ((2010)) Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer. BMC Genomics 11:: 676.
8. Pio R, Blanco D, Pajares MJ, Aibar E, Durany O, et al. ((2010)) Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. BMC Genomics 11:: 352.
9. Misquitta-Ali CM, Cheng E, O'Hanlon D, Liu N, McGlade CJ, et al. ((2011)) Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol 31:: 138--150.
10. Groeger AM, Esposito V, De Luca A, Cassandro R, Tonini G, et al. ((2004)) Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology 44:: 54--63.
11. Karczmarek-Borowska B, Filip A, Wojcierowski J, Smolen A, Korobowicz E, et al. ((2006)) Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer 51:: 61--69.
12. Shultz JC, Goehe RW, Murudkar CS, Wijesinghe DS, Mayton EK, et al. ((2011)) SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Mol Cancer Res 9:: 889--900.
13. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, et al. ((2006)) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66:: 283--289.
14. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, et al. ((2007)) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14:: 185--193.
15. Pino I, Pio R, Toledo G, Zabalegui N, Vicent S, et al. ((2003)) Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 41:: 131--143.
16. Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK, et al. ((1997)) Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 3:: 2237--2246.
17. Castano Z, Vergara-Irigaray N, Pajares MJ, Montuenga LM, Pio R, ((2008)) Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. Int J Cancer 122:: 1512--1520.
18. Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, Lopez-Picazo JM, et al. ((2010)) The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res 16:: 4113--4125.
19. Goehe RW, Shultz JC, Murudkar C, Usanovic S, Lamour NF, et al. ((2010)) hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. J Clin Invest 120:: 3923--3939.
20. Zerbe LK, Pino I, Pio R, Cosper PF, Dwyer-Nield LD, et al. ((2004)) Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog 41:: 187--196.
21. Peebles KA, Dwyer-Nield LD, Malkinson AM (2007) Altered expression of splicing factor, heterogeneous nuclear ribonucleoprotein A2/B1, in mouse lung neoplasia. Mol Carcinog. 2007/05/05 ed. 887-900.
22. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. ((2001)) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98:: 13790--13795.
23. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, et al. ((2002)) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:: 816--824.
24. Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, et al. ((2007)) Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer 56:: 175--184.
25. Yap YL, Lam DC, Luc G, Zhang XW, Hernandez D, et al. ((2005)) Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. Nucleic Acids Res 33:: 409--421.
26. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. ((2008)) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14:: 822--827.
27. Sueoka E, Sueoka N, Iwanaga K, Sato A, Suga K, et al. ((2005)) Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction. Lung Cancer 48:: 77--83.
28. Pio R, Zudaire I, Pino I, Castano Z, Zabalegui N, et al. ((2004)) Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer. Cancer Res 64:: 4171--4179.
29. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, et al. ((2011)) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:: 64--69.
30. Abdel-Wahab O, Levine R, ((2011)) The spliceosome as an indicted conspirator in myeloid malignancies. Cancer Cell 20:: 420--423.
31. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, et al. ((2011)) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365:: 1384--1395.
32. Quesada V, Conde L, Villamor N, Ordoñez GR, Jares P, et al. ((2011)) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44:: 47--52.
33. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, et al. ((2011)) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365:: 2497--2506.
34. Ebert B, Bernard OA, ((2011)) Mutations in RNA splicing machinery in human cancers. N Engl J Med 365:: 2534--2535.
35. van Alphen RJ, Wiemer EA, Burger H, Eskens FA, ((2009)) The spliceosome as target for anticancer treatment. Br J Cancer 100:: 228--232.
36. Yi Y, Nandana S, Case T, Nelson C, Radmilovic T, et al. ((2009)) Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer. Mol Cytogenet 2:: 18.
37. Wang X, Pankratz VS, Fredericksen Z, Tarrell R, Karaus M, et al. ((2010)) Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 19:: 2886--2897.
38. Li Z, Putzer BM, ((2008)) Spliceosomal protein E regulates neoplastic cell growth by modulating expression of cyclin E/CDK2 and G2/M checkpoint proteins. J Cell Mol Med 12:: 2427--2438.
39. Riemenschneider MJ, Knobbe CB, Reifenberger G, ((2003)) Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer 104:: 752--757.
40. Kuo WP, Jenssen TK, Park PJ, Lingen MW, Hasina R, et al. ((2002)) Gene expression levels in different stages of progression in oral squamous cell carcinoma. Proc AMIA Symp. pp. 415--419.
41. Jia D, Wei L, Guo W, Zha R, Bao M, et al. ((2011)) Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology.
42. Kushner JP, Boll D, Quagliana J, Dickman S, ((1976)) Elevated methionine-tRNA synthetase activity in human colon cancer. Proc Soc Exp Biol Med 153:: 273--276.
43. Pacher M, Seewald MJ, Mikula M, Oehler S, Mogg M, et al. ((2007)) Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis 28:: 49--59.
44. Park SW, Kim SS, Yoo NJ, Lee SH, ((2010)) Frameshift Mutation of MARS Gene Encoding an Aminoacyl-tRNA Synthetase in Gastric and Colorectal Carcinomas with Microsatellite Instability. Gut Liver 4:: 430--431.
45. Ou JH, Yen TS, Wang YF, Kam WK, Rutter WJ, ((1987)) Cloning and characterization of a human ribosomal protein gene with enhanced expression in fetal and neoplastic cells. Nucleic Acids Res 15:: 8919--8934.
46. Takashima N, Ishiguro H, Kuwabara Y, Kimura M, Haruki N, et al. ((2006)) Expression and prognostic roles of PABPC1 in esophageal cancer: correlation with tumor progression and postoperative survival. Oncol Rep 15:: 667--671.
47. van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, et al. ((2005)) High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 44:: 438--449.
48. Liu Y, Zhu X, Zhu J, Liao S, Tang Q, et al. ((2007)) Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep 18:: 943--951.
49. Chen R, Feng C, Xu Y, ((2011)) Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression. J Int Med Res 39:: 533--540.
50. Comtesse N, Keller A, Diesinger I, Bauer C, Kayser K, et al. ((2007)) Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer 120:: 2538--2544.
51. Katzenellenbogen RA, Vliet-Gregg P, Xu M, Galloway DA, ((2010)) Cytoplasmic poly(A) binding proteins regulate telomerase activity and cell growth in human papillomavirus type 16 E6-expressing keratinocytes. J Virol 84:: 12934--12944.
52. Wong RW, ((2010)) Interaction between Rae1 and cohesin subunit SMC1 is required for proper spindle formation. Cell Cycle 9:: 198--200.
53. Wong RW, Blobel G, Coutavas E, ((2006)) Rae1 interaction with NuMA is required for bipolar spindle formation. Proc Natl Acad Sci U S A 103:: 19783--19787.
54. Cuende J, Moreno S, Bolanos JP, Almeida A, ((2008)) Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation. Oncogene 27:: 3339--3344.
55. Jeganathan KB, Baker DJ, van Deursen JM, ((2006)) Securin associates with APCCdh1 in prometaphase but its destruction is delayed by Rae1 and Nup98 until the metaphase/anaphase transition. Cell Cycle 5:: 366--370.
56. Miura K, Fujibuchi W, Sasaki I, ((2011)) Alternative pre-mRNA splicing in digestive tract malignancy. Cancer Sci 102:: 309--316.
57. Melcher T, Maas S, Herb A, Sprengel R, Higuchi M, et al. ((1996)) RED2, a brain-specific member of the RNA-specific adenosine deaminase family. J Biol Chem 271:: 31795--31798.
58. Higuchi M, Maas S, Single FN, Hartner J, Rozov A, et al. ((2000)) Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 406:: 78--81.
59. Flanagan JM, Funes JM, Henderson S, Wild L, Carey N, et al. ((2009)) Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets. Mol Cancer Ther 8:: 249--260.
60. Martinez HD, Jasavala RJ, Hinkson I, Fitzgerald LD, Trimmer JS, et al. ((2008)) RNA editing of androgen receptor gene transcripts in prostate cancer cells. J Biol Chem 283:: 29938--29949.
61. Maas S, Patt S, Schrey M, Rich A, ((2001)) Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A 98:: 14687--14692.
62. Ishiuchi S, Yoshida Y, Sugawara K, Aihara M, Ohtani T, et al. ((2007)) Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 27:: 7987--8001.
63. Paz N, Levanon EY, Amariglio N, Heimberger AB, Ram Z, et al. ((2007)) Altered adenosine-to-inosine RNA editing in human cancer. Genome Res 17:: 1586--1595.
64. Cenci C, Barzotti R, Galeano F, Corbelli S, Rota R, et al. ((2008)) Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J Biol Chem 283:: 7251--7260.
65. Galeano F, Leroy A, Rossetti C, Gromova I, Gautier P, et al. ((2010)) Human BLCAP transcript: new editing events in normal and cancerous tissues. Int J Cancer 127:: 127--137.
66. Inamura K, Fujiwara T, Hoshida Y, Isagawa T, Jones MH, et al. ((2005)) Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene 24:: 7105--7113.
67. Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, et al. ((1993)) Human epithelial ovarian cancer allelotype. Cancer Res 53:: 2393--2398.
68. Sakata K, Tamura G, Nishizuka S, Maesawa C, Suzuki Y, et al. ((1997)) Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach. Genes Chromosomes Cancer 18:: 318--321.
69. Ohgaki K, Iida A, Kasumi F, Sakamoto G, Akimoto M, et al. ((1998)) Mapping of a new target region of allelic loss to a 6-cM interval at 21q21 in primary breast cancers. Genes Chromosomes Cancer 23:: 244--247.
70. Yamamoto N, Uzawa K, Miya T, Watanabe T, Yokoe H, et al. ((1999)) Frequent allelic loss/imbalance on the long arm of chromosome 21 in oral cancer: evidence for three discrete tumor suppressor gene loci. Oncol Rep 6:: 1223--1227.
71. Mayama T, Fukushige S, Shineha R, Nishihira T, Satomi S, et al. ((2000)) Frequent loss of copy number on the long arm of chromosome 21 in human esophageal squamous cell carcinoma. Int J Oncol 17:: 245--252.
72. Sato S, Nakamura Y, Tsuchiya E, ((1994)) Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 54:: 5652--5655.
73. Kohno T, Kawanishi M, Matsuda S, Ichikawa H, Takada M, et al. ((1998)) Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including the ANA gene in human lung carcinoma. Genes Chromosomes Cancer 21:: 236--243.
74. Lee EB, Park TI, Park SH, Park JY, ((2003)) Loss of heterozygosity on the long arm of chromosome 21 in non-small cell lung cancer. Ann Thorac Surg 75:: 1597--1600.
75. Tseng RC, Chang JW, Hsien FJ, Chang YH, Hsiao CF, et al. ((2005)) Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int J Cancer 117:: 241--247.
76. Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, et al. ((2000)) Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer 82:: 65--73.
77. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (2004) Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of tumours. 3rd ed. Lyon: IARC Press.